Search hospitals

>

Missouri

>

Saint Louis

Siteman Cancer Center at Christian Hospital

Claim this profile

Saint Louis, Missouri 63110

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Cancer

Conducts research for Pancreatic Cancer

Conducts research for Lymphoma

491 reported clinical trials

69 medical researchers

Photo of Siteman Cancer Center at Christian Hospital in Saint LouisPhoto of Siteman Cancer Center at Christian Hospital in Saint LouisPhoto of Siteman Cancer Center at Christian Hospital in Saint Louis

Summary

Siteman Cancer Center at Christian Hospital is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Pancreatic Cancer, Lymphoma and other specialties. Siteman Cancer Center at Christian Hospital is involved with conducting 491 clinical trials across 609 conditions. There are 69 research doctors associated with this hospital, such as Robert J. Hayashi, Brian A Van Tine, M.D., Ph.D., Douglas R. Adkins, and Premal H Thaker, M.D., M.S..

Area of expertise

1

Lung Cancer

Global Leader

Siteman Cancer Center at Christian Hospital has run 103 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

Siteman Cancer Center at Christian Hospital has run 91 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Siteman Cancer Center at Christian Hospital

Lung Cancer

Breast Cancer

Prostate Cancer

Skin Cancer

Breast cancer

Cancer

Small Cell Lung Cancer

Esophageal cancer

Brain Tumor

Esophageal Adenocarcinoma

Image of trial facility.

Radiotherapy

for Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Siteman Cancer Center at Christian Hospital?

Where is Siteman Cancer Center at Christian Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Siteman Cancer Center at Christian Hospital accept?

What awards or recognition has Siteman Cancer Center at Christian Hospital received?